Numinus Wellness Says Cedar Clinical Research (CCR) Is A Top Research Site For MindMed's Phase 2b Study Evaluating MM-120
Portfolio Pulse from Benzinga Newsdesk
Numinus Wellness announced that Cedar Clinical Research (CCR), a subsidiary of Numinus, has been selected as a top research site for MindMed's Phase 2b study evaluating MM-120. This partnership will advance the development of psychedelic-assisted therapies.
June 05, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MindMed's partnership with Numinus Wellness' subsidiary, Cedar Clinical Research, for its Phase 2b study on MM-120 may positively impact the company's stock.
The partnership with Cedar Clinical Research, a top research site, will help MindMed advance its Phase 2b study on MM-120. This collaboration may lead to positive results and increased investor confidence, potentially driving the stock price up.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80